POEMs

2013 ACC/AHA Cholesterol Guideline Greatly Increases Number Eligible for Statin Treatment

 


FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.


FREE PREVIEW. Purchase online access to read the full version of this article.

Am Fam Physician. 2014 Aug 15;90(4):online.

  Related Practice Guidelines: ACC/AHA Release Updated Guidelines on the Treatment of Blood Cholesterol to Reduce ASCVD Risk

  Related Editorial: Should Family Physicians Follow the New ACC/AHA Cholesterol Treatment Guideline? Yes: Implementing the New ACC/AHA Cholesterol Guideline Will Improve Cardiovascular Outcomes

  Related Editorial: Should Family Physicians Follow the New ACC/AHA Cholesterol Treatment Guideline? Not Completely: Why It Is Right to Drop LDL-C Targets, but Wrong to Recommend Statins at a 7.5% 10-Year Risk

Clinical Question

How many more adults will be eligible for statin therapy under the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline than under previous guidelines?

Bottom Line

The new guideline from the ACC/AHA increases the number of adults between 40 and 75 years of age who are eligible to take statins by 12.8 million. The largest increases were among adults who would take statins for primary prevention and for adults between 60 and 75 years of age. The authors estimate that the switch could prevent 475,000 future cardiovascular events in this population. (Level of Evidence = 2c)

Synopsis

The 2004 guidelines from the Third Adult Treatment Panel (ATP III) of the National Cholesterol Education Program recommended statin therapy on the basis of the presence of specific risk factors, such as diabetes mellitus or cardiovascular disease (CVD), and on specified treatment targets according to risk level. The 2013 ACC/AHA guideline suggests statins for all adults at risk of CVD, regardless of low-density lipoprotein cholesterol (LDL-C) levels. The research team used National Health and Nutrition Examination Survey (NHANES) data from 2005 to 2010 to determine the proportion of adults who would be eligible to take statins under each guideline and then extrapolated those results to the U.S. population at large. They also compared the risk profiles of patients eligible for statins under each approach and the two different calculators used to estimate risk with each guideline. For the analysis, they used fasting blood samples of a subset of 3,773 adults between 40 and 75 years of age.

Of the study sample, 1,583 patients (42.0%) would receive a statin under the ATP III guidelines, whereas 2,135 (56.6%) would receive a statin under the 2013 ACC/AHA guideline, for an increase of 599 newly eligible adults (15.9%; higher than the net difference because some participants eligible under the ATP III guidelines would not be eligible under the new guideline). When these results were extrapolated to 115 million U.S. adults between 40 and 75 years of age, 43.2 million patients (37.5%) would be prescribed statins under the ATP III guidelines and 56.0 million patients (48.6%) were eligible under the new ACC/AHA guideline, representing an increase of 12.8 million adults. Of the newly eligible U.S. adults, 61.7% are men, the median age is 63.4 years, and the median LDL-C level is 105.2 mg per dL (2.72 mmol per L). The greatest difference in cholesterol recommendations is among adults 60 to 75 years of age (47.8% eligible under ATP III vs. 77.3% under ACC/ AHA). This study may be limited by the accuracy and representativeness of the NHANES data, including self-reporting of statin use and lack of data on peripheral vascular disease or transient ischemic attacks, which may underestimate rates of CVD in the sample.

Study design: Cross-sectional

Funding source: Foundation

Setting: Population-based

Reference: Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr., et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med.. 2014; 370( 15): 1422– 1431.

POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP,search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

A collection of POEMs published in AFP is available at http://www.aafp.org/afp/poems.



 

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Sep 15, 2016

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article